Carcinoembryonic Antigen (CEA), Peritoneal Fluid
Carcinoembryonic antigen (CEA) belongs to a group of oncofetal protein-based tumor markers. Carcinoembryonic antigen is a glycoprotein normally found in embryonic endodermal epithelium and in the fetal serum. After birth CEA production is stopped and in adulthood levels are barely measurable. Serum CEA concentrations are typically increased in persons with primary colorectal cancer. Results will vary depending on the methodology used, therefore erroneous interpretations can result unless the testing is performed using the same methodology throughout. Serial monitoring is recommended in some cases and, as previously stated, the methodology must be consistent throughout the course. Elevated serum CEA concentrations have also been detected in patients with other malignancies including gastrointestinal tract, breast, lung, ovarian, prostatic, liver, and pancreatic cancers; and in nonmalignant disease, especially patients who are older or who are smokers. Normal results do not exclude the presence of a malignant disease. CEA has been useful in disease monitoring including assessment of prognosis, recurrence of tumors after surgical removal, and effectiveness of therapy. CEA concentrations generally fall to normal or near normal levels within 1 to 4 months after surgical removal of cancerous tissue. A subsequent rise in CEA may be the first indication of recurrence, and may precede physical signs and symptoms. Sustained elevated CEA concentrations can indicate ineffective therapy or metastasis.
- To assess the stage and extent of colon cancer
- To assess the stage and extent of other cancers (gastrointestinal, breast, ovarian, pancreatic, etc.)
- Monitoring and management of cancer therapy (eg, assessing the effectiveness of therapy)
- Prognostic post operative monitoring of patients with colon cancer
- Detection of recurrent colorectal cancer
Increased in:
- Colon cancer
- Rectum cancer
- Lung cancer
- Pancreatic cancer
- Breast cancer
- Stomach cancer
- Liver cancer
- Ovary cancer
- Cigarette smokers
- Liver disease other than cancer
- Benign gastrointestinal diseases (peptic ulcer, pancreatitis, ulcerative colitis)
- Benign breast disease
- Pulmonary infections and COPD
- Renal failure
Levels >20 ng/mL are usually seen in malignancy
Nonsmokers: ≤3.0 ng/mL
Smokers: ≤5.0 ng/mL)
Enzyme Immunoassay.
Peritoneal fluid collected in a sterile container.
Stability
- Ambient - 24 hours
- Refrigerated - 3-5 days
- Frozen - 30 days
- Cancer Detect Prev. 1988;12(1-6):321-55. [PMID: 3052834]
- Cancer Invest. 2005;23(4):338-51. [PMID: 16100946]
- Clin Chem. 2001 Apr;47(4):624-30. [PMID: 11274010]
- Ann Clin Biochem. 2004;41:370. [PMID: 15333188]